BPC-157
Also known as: Body Protection Compound 157, BPC 157, Body Protective Compound 157, Stable Gastric Pentadecapeptide BPC 157, GEPPPGKPADDAGLV
Synthetic pentadecapeptide / gastric cytoprotective peptide
What it is
BPC-157 is a peptide people use to speed up recovery from soft-tissue injuries like tendon, ligament, and muscle damage. It's also used for gut inflammation and ulcer healing. Not FDA-approved; most research is in animals, with a few small human studies.
The scientific side
BPC-157 is described as a synthetic pentadecapeptide derived from a human gastric protein fragment with reported cytoprotective and regenerative properties. It activates several overlapping pathways including VEGFR2 and nitric oxide synthesis via the Akt-eNOS axis, promoting angiogenesis, fibroblast activity, and neuromuscular stabilization; it also engages ERK1/2 signaling and exerts anti-inflammatory effects. It enhances growth hormone receptor expression and pathways involved in cell growth and angiogenesis while reducing inflammatory cytokines. In wound healing, it acts by resolving vessel constriction, stabilizing platelet plugs, and counteracting arterial and venous thrombosis, and it rapidly increases various gene expression in rat excision skin wounds. In ocular models, it is described as activating collateral pathways to counteract occlusion syndromes and normalize intraocular pressure. It is reported to be stable in gastric juice and to demonstrate activity via oral, parenteral, and topical routes. It is metabolized in the liver, with a half-life of less than 30 minutes, and is cleared by the kidneys.
Class: Synthetic pentadecapeptide / gastric cytoprotective peptide
At a glance
| What it is | A 15-amino-acid synthetic peptide (GEPPPGKPADDAGLV) based on a protein found in human gastric juice. |
|---|---|
| FDA status | Not approved for any use. An FDA advisory committee voted 8-6 in July 2026 to let compounding pharmacies make it; that vote is a recommendation only. |
| Used for | Tendon, ligament, muscle and gut healing, mostly on the strength of animal studies. |
| Human evidence | Three small uncontrolled pilot studies (2, 12 and 16 people). No completed, published randomized trial. |
| Half-life | Under 30 minutes in rats and dogs. No human data. |
| Banned in sport | Yes. WADA lists it by name under S0 Non-Approved Substances, prohibited at all times. |
| Common forms | Injection under the skin or into muscle; oral capsules. Sold mostly as an unregulated "research chemical". |
What is BPC-157?
BPC-157 ("Body Protection Compound 157") is a synthetic peptide of 15 amino acids, Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is a fragment of a larger protective protein that its discoverers isolated from human gastric juice. Unlike many peptides it stays stable in stomach acid, which is why it is studied by mouth as well as by injection.
It is best known for tendon, ligament and muscle recovery, and for gut problems like ulcers and inflammatory bowel disease. It is often stacked with TB-500. Almost all of that reputation comes from rodent studies.
How does it work?
In animal and cell studies, BPC-157 appears to act on blood-vessel growth and repair. It activates the VEGFR2 receptor and the Akt-eNOS nitric oxide pathway, promotes new blood vessels (angiogenesis) and fibroblast activity, and engages ERK1/2 signaling. These effects are proposed to matter most in tissues with a poor blood supply, like tendons. Reviews also describe increased growth hormone receptor expression and lower inflammatory cytokines.
None of these mechanisms has been confirmed in humans. The pharmacokinetic figures below come from rats and dogs.
Pharmacokinetics
| Half-life | Under 30 minutes in rats and dogs, IV and intramuscular (no human data) |
|---|---|
| Metabolism | Rapidly broken down into small peptide fragments and then single amino acids (animal data) |
| Clearance | Excreted mainly in urine and bile (animal data) |
| Route | Studied by injection (IV, intramuscular, subcutaneous) and by mouth; intramuscular bioavailability about 14-19% in rats and 45-51% in dogs |
Is it FDA-approved?
No. BPC-157 has never been approved by the FDA for any use, and no company has completed the trials an approval would need.
What changed in 2026 is compounding, not approval. In April 2026, FDA moved BPC-157 off its list of compounding substances with significant safety risks ("Category 2") after the nominators withdrew it. In July 2026, FDA's Pharmacy Compounding Advisory Committee voted 8-6, with 1 abstention, to recommend adding it to the list of substances compounding pharmacies may use. The vote is not binding: FDA would still have to accept it and complete proposed and final rulemaking. FDA's own reviewers had recommended against it, citing short, underpowered studies.
- WADA: S0 Non-Approved Substances (named in the 2026 Prohibited List; prohibited at all times)
History
The idea dates to 1975, when Predrag Sikiric, then a medical student in Zagreb, reasoned that the stomach must make its own anti-stress compounds. His team spent years collecting gastric juice from clinics, emergency rooms and pig slaughterhouses. Sikiric says that in 1989 they found a protective protein, and from it a 15-amino-acid fragment he named BPC 157.
In 1993 Sikiric signed a contract with the Croatian drug maker PLIVA, which developed the peptide as PL 14736 alongside university researchers and the American company Parke-Davis. In the early 2000s PLIVA ran two early-stage trials in ulcerative colitis. The full results were never published; a short 2005 write-up reported a positive effect in the second trial that did not reach statistical significance.
In 2006 PLIVA's research institute was sold to GlaxoSmithKline, which dropped the project. At the end of 2009 the rights returned to Sikiric, whose group has continued mostly rodent research. Around 2010, bodybuilders on online forums began sourcing BPC-157 from suppliers in China, and a grey market grew from there.
Regulatory timeline
- September 29, 2023FDA places BPC-157 in Category 2 (503A): substances that may present significant safety risks in compounding, citing immunogenicity, impurity concerns and limited safety data. Source
- April 2026FDA lists BPC-157 under "nominated but withdrawn": the nominators withdrew it, so it is no longer in Category 2. FDA's page was updated April 22, 2026. Source
- July 23, 2026FDA's Pharmacy Compounding Advisory Committee votes 8-6, with 1 abstention, to recommend BPC-157 for the 503A bulks list. The vote is a non-binding recommendation. Source
- As of October 2026Still not FDA-approved for any use. Compounding would still require FDA to accept the recommendation and complete rulemaking. Source
Side effects
There is no reliable human side-effect data. The three published human pilot studies (2, 12 and 16 people) reported no adverse events, but they had no control groups and were far too small to detect uncommon problems. The only registered trial, an oral phase 1 study in 42 healthy volunteers (NCT02637284), never posted results.
Users online have described side effects including whole-body itching, intense anxiety and anhedonia (loss of pleasure). These are anecdotes, not evidence that BPC-157 caused them. Because the peptide promotes blood-vessel growth, reviewers have raised a theoretical concern about tumor growth; no study has shown it causes or speeds up cancer, and none has tested long-term use. Grey-market vials add their own risks: contamination, wrong dose or a different substance.
Who should not use it
- No established contraindications: BPC-157 has never been through the trials that would define them.
- Competitive athletes: prohibited at all times under WADA S0.
- Pregnancy, breastfeeding, and people with active or past cancer were not studied; the theoretical angiogenesis concern makes caution reasonable.
No controlled human trial has published adverse-event data. NCT02637284 (oral, 42 planned participants, sponsor PharmaCotherapia) has no posted results and its ClinicalTrials.gov status is "Unknown".
What does the research show?
A 2025 systematic review in orthopaedic sports medicine found 36 eligible studies published between 1993 and 2024: 35 preclinical and 1 clinical. In animals, BPC-157 improved functional, structural and biomechanical outcomes in muscle, tendon, ligament and bone injuries. The review found no clinical safety data.
The human studies are small and uncontrolled. In a retrospective chart review of knee injections, 14 of 16 people reported relief from knee pain. In a pilot study of 12 women with interstitial cystitis, bladder-wall injections during cystoscopy resolved symptoms in 10. In a 2-person safety pilot, IV infusions of 10 mg and 20 mg caused no measurable changes in heart, liver, kidney, thyroid or glucose tests. A 2025 narrative review concluded BPC-157 "should be considered investigational, and its use approached with caution."
Studied for
- Tendon, ligament and muscle injury (animal studies)
- Bone healing (animal studies)
- Ulcerative colitis (two unpublished PLIVA trials, early 2000s)
- Knee pain (16-person retrospective case series)
- Interstitial cystitis (12-person pilot study)
FAQ
Is BPC-157 FDA-approved?
No, not for any use. The July 2026 advisory committee vote was about compounding, not approval, and it was a non-binding recommendation.
Can a compounding pharmacy make BPC-157 now?
Not yet under the normal 503A route. BPC-157 left Category 2 in April 2026 and the advisory committee recommended it in July 2026, but FDA still has to accept that recommendation and finish proposed and final rulemaking before it is added to the bulks list.
Is BPC-157 safe?
Nobody knows. The published human data are three uncontrolled pilot studies totalling 30 people, which reported no adverse events but cannot establish safety. There are no long-term human data.
Oral or injection: which works better?
There is no human comparison. BPC-157 is stable in gastric juice and works by mouth in animal studies, but the only oral human trial never published results. In rats and dogs, intramuscular bioavailability was about 14-19% and 45-51% respectively.
Is BPC-157 banned in sports?
Yes. The WADA Prohibited List names BPC-157 under S0 Non-Approved Substances, which is prohibited at all times, in and out of competition. Some published reviews say otherwise; the current list is the authority.
Can BPC-157 cause cancer?
No study has shown that it causes or speeds up cancer. Because it promotes blood-vessel growth, one review team calls this "a plausible tumor-promoting hazard". Sikiric's group counters that BPC-157 controls vessel growth rather than driving it and reports anti-tumor effects in animal and cell studies. Neither side has long-term tumor studies in animals or people.
How long does BPC-157 stay in the body?
In rats and dogs, its half-life was under 30 minutes and it was broken down into amino acids. There are no human half-life measurements.
Sources: [5]
Does it need lab monitoring?
There is a separate lab-monitoring guide for BPC-157, linked in the sidebar, covering the baseline, mid-cycle and post-cycle tests people commonly run.
Citations
- Józwiak M, et al. Multifunctionality and possible medical application of the BPC 157 peptide: literature and patent review. Pharmaceuticals (Basel) 2025. PMID 40005999
- Sikiric P, et al. Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. Curr Med Chem 2012. PMID 22300085
- McGuire FP, et al. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr Rev Musculoskelet Med 2025. PMID 40789979
- Vasireddi N, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J 2025. PMID 40756949
- He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogs. Front Pharmacol 2022. PMID 36588717
- FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- Todd S, Lawrence L. FDA panel backs compounded BPC-157, KPV peptides in win for RFK Jr. STAT, July 23, 2026. statnews.com/2026/07/23/fda-panel-okays-peptides-compound-pharmacies-bpc-157-kpv
- Steinzor P. FDA panel backs 6 peptides for compounding. AJMC, July 31, 2026. ajmc.com/view/fda-panel-backs-6-peptides-for-compounding
- Talpos S (Undark). BPC-157 peptide: a secretive Croatian researcher's 50-year quest. STAT, June 1, 2026. statnews.com/2026/06/01/bpc-157-researcher-predrag-sikiric-addesses-skeptics-questions
- Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med 2025. PMID 40131143
- Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med 2024. PMID 39325560
- Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med 2021. PMID 34324435
- NCT02637284: Phase I pilot study of PCO-02 (oral BPC-157) in healthy volunteers. clinicaltrials.gov/study/NCT02637284
- Talpos S (Undark). BPC-157: the peptide with big claims and scant evidence. STAT, February 3, 2026. statnews.com/2026/02/03/bpc-157-peptide-science-safety-regulatory-questions
- Józwiak M, et al. Reply to Sikiric et al. Pharmaceuticals (Basel) 2025. PMID 41155566
- World Anti-Doping Agency: Prohibited List 2026, section S0 (Non-Approved Substances). wada-ama.org/en/prohibited-list
- USADA: BPC-157: experimental peptide creates risk for athletes. usada.org/spirit-of-sport/bpc-157-peptide-prohibited
- Sikiric P, et al. BPC 157 therapy: targeting angiogenesis and nitric oxide's cytotoxic and damaging actions. Pharmaceuticals (Basel) 2025. PMID 41155565
Sources
- Józwiak 2025. Józwiak M, et al. Multifunctionality and possible medical application of the BPC 157 peptide: literature and patent review. Pharmaceuticals (Basel) 2025. pubmed.ncbi.nlm.nih.gov/40005999
- Sikiric 2012. Sikiric P, et al. Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. Curr Med Chem 2012. pubmed.ncbi.nlm.nih.gov/22300085
- He 2022. He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogs. Front Pharmacol 2022. pubmed.ncbi.nlm.nih.gov/36588717
- Vasireddi 2025. Vasireddi N, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J 2025. pubmed.ncbi.nlm.nih.gov/40756949
- McGuire 2025. McGuire FP, et al. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr Rev Musculoskelet Med 2025. pubmed.ncbi.nlm.nih.gov/40789979
- Lee 2021. Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med 2021. pubmed.ncbi.nlm.nih.gov/34324435
- Lee 2024. Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med 2024. pubmed.ncbi.nlm.nih.gov/39325560
- Lee 2025. Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med 2025. pubmed.ncbi.nlm.nih.gov/40131143
- Sikiric 2025. Sikiric P, et al. BPC 157 therapy: targeting angiogenesis and nitric oxide's cytotoxic and damaging actions. Pharmaceuticals (Basel) 2025. pubmed.ncbi.nlm.nih.gov/41155565
- Józwiak 2025 reply. Józwiak M, et al. Reply to Sikiric et al. Pharmaceuticals (Basel) 2025. pubmed.ncbi.nlm.nih.gov/41155566
- FDA. FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- FDA (2024 archive). FDA: the same page as archived September 28, 2024, listing BPC-157 in Category 2 from September 29, 2023. web.archive.org/web/20240928064141/https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- STAT, July 2026. Todd S, Lawrence L. FDA panel backs compounded BPC-157, KPV peptides in win for RFK Jr. STAT, July 23, 2026. statnews.com/2026/07/23/fda-panel-okays-peptides-compound-pharmacies-bpc-157-kpv
- AJMC, July 2026. Steinzor P. FDA panel backs 6 peptides for compounding. AJMC, July 31, 2026. ajmc.com/view/fda-panel-backs-6-peptides-for-compounding
- STAT, June 2026. Talpos S (Undark). BPC-157 peptide: a secretive Croatian researcher's 50-year quest. STAT, June 1, 2026. statnews.com/2026/06/01/bpc-157-researcher-predrag-sikiric-addesses-skeptics-questions
- STAT, February 2026. Talpos S (Undark). BPC-157: the peptide with big claims and scant evidence. STAT, February 3, 2026. statnews.com/2026/02/03/bpc-157-peptide-science-safety-regulatory-questions
- WADA. World Anti-Doping Agency: Prohibited List 2026, section S0 (Non-Approved Substances). wada-ama.org/en/prohibited-list
- USADA. USADA: BPC-157: experimental peptide creates risk for athletes. usada.org/spirit-of-sport/bpc-157-peptide-prohibited
- ClinicalTrials.gov. NCT02637284: Phase I pilot study of PCO-02 (oral BPC-157) in healthy volunteers. clinicaltrials.gov/study/NCT02637284
Administration & storage
- Administration
- Intravesical injection (PMID: 39325560)Intraperitoneal injection (PMID: 36551977)Intramuscular injection — preclinical (PMID: 42198317)Intravenous — human pharmacokinetic pilot (PMID: 42198317)Intraarticular injection — retrospective clinical study (PMID: 40756949)Oral/drinking water — animal studies (PMID: 36551977)Topical — animal studies (PMID: 36551977)
- Storage
- No storage conditions for BPC-157 formulations are described in the reviewed abstracts.
- Cautions
- No pharmaceutical-grade formulation has been developed or validated; the peptide lacks BCS classification, permeability characterization, and formal excipient compatibility studies.,Available human clinical data derive from fewer than 30 subjects across three uncontrolled pilot studies, none of which employed standardized pharmaceutical preparations.,Adverse effects are possible due to unregulated manufacturing, contamination, or unknown clinical safety profile.,Human pharmacokinetic data are critically undercharacterized; a sub-30-min plasma half-life has been confirmed only in a two-subject preliminary human pilot.,Sterile technique is essential for any injectable preparation; compounding pharmacy sourcing introduces additional quality variability.
Legal & regulatory status
Not approved by the US Food and Drug Administration for any therapeutic indication (PMID: 39325560, PMID: 40005999, PMID: 42198317). No completed Phase II clinical trial as of the reviewed literature.
Prohibited at all times under WADA S0 (non-approved substances), per the 2026 World Anti-Doping Code Prohibited List. Verified against the current WADA list as of October 2026.
Not stated in reviewed literature — requires manual verification
What it's studied for
- Interstitial cystitis (bladder pain syndrome) Human observational
- Pilot study (n=12 women, mean age 58.3 years) who had failed pentosan polysulfate. Intravesical injection of BPC-157 (10 mg total) around the area of bladder inflammation during a single procedure. 10 of 12 patients reported complete symptom resolution (100% success); the remaining 2 rated success at 80%. All 12 patien PMID 39325560 Lee E, et al. Alternative Therapies in Health and Medicine. 2024.
- Musculoskeletal soft tissue healing (tendon, ligament, skeletal muscle, bone) Animal studies only
- Review of preclinical literature. All studies demonstrated consistently positive and prompt healing effects for various injury types (traumatic and systemic) in small rodent models. Efficacy in humans not yet confirmed. Few adverse reactions reported. PMID 30915550 Gwyer D, et al. Cell and Tissue Research. 2019.
- Systematic review (36 studies: 35 preclinical, 1 clinical). Preclinical studies showed improved functional, structural, and biomechanical outcomes in muscle, tendon, ligament, and bone injuries. One retrospective clinical study (n=12 patients with chronic knee pain): 7 of 12 reported relief >6 months after intraarticul PMID 40756949 Vasireddi N, et al. HSS Journal. 2025.
- Narrative review. Broad preclinical support for regenerative/cytoprotective effects. Only three pilot studies examined BPC-157 in humans (intraarticular knee pain, interstitial cystitis, IV safety/PK). No adverse effects reported in these limited human studies. Rigorous large-scale trials lacking. PMID 40789979 McGuire FP, et al. Current Reviews in Musculoskeletal Medicine. 2025.
- Review of rat injury studies. BPC-157 therapy shown to promote healing of myotendinous junction, muscle, tendon, ligament, and bone injuries, applied intraperitoneally, in drinking water, or topically. Effective across µg–ng dose regimens. Lethal dose not achieved in safety studies. PMID 36551977 Staresinic M, et al. Biomedicines. 2022.
- Wound healing (skin, gastrointestinal, and other tissues) Animal studies only
- Review of rat models. BPC-157 shown effective for incisional/excisional wounds, deep burns, diabetic ulcers, and alkali burns; simultaneous healing of cutaneous and fistular wounds. Effective via multiple equipotent routes at the same dose range. Previously employed in ulcerative colitis and multiple sclerosis trials w PMID 34267654 Seiwerth S, et al. Frontiers in Pharmacology. 2021.
- Gastrointestinal anastomosis healing and fistula therapy Animal studies only
- Review of rat studies. BPC-157 therapy shown to promote healing of various anastomoses (esophagogastric, colocolonic, jejunoileal, ileoileal) and fistulas (colocutaneous, gastrocutaneous, esophagocutaneous, duodenocutaneous, vesicovaginal, colovesical, rectovaginal), alongside concomitant GI disturbances. PMID 39204186 Bajramagic S, et al. Pharmaceuticals. 2024.
- Ocular conditions including glaucoma, retinal ischemia, and corneal injury Animal studies only
- Review of rat glaucoma and ocular injury models. BPC-157 normalized intraocular pressure in glaucomatous rats (three of four episcleral veins cauterized), maintained retinal integrity, recovered pupil function, and counteracted corneal injuries and dry eye. Data are preclinical only. PMID 37513963 Sikiric P, et al. Pharmaceuticals. 2023.
- Muscle (striated, smooth, cardiac) function and recovery Animal studies only
- Review of rat studies. BPC-157 shown to recover muscle disabilities from diverse causes (succinylcholine, vascular occlusion, spinal cord compression, stroke, TBI, electrolyte disturbances, neurotoxins, neuroleptics, alcohol, serotonin syndrome, NO-system blockade, tumor-cachexia) and to support sphincter function reco PMID 36551977 Staresinic M, et al. Biomedicines. 2022.
- Biopharmaceutical characterization and pharmacokinetics Mixed
- Narrative review. Preclinical ADME study in two species confirmed sub-30-min plasma half-life, linear dose-proportional kinetics, and intramuscular bioavailability of 14–51% depending on species. A two-subject human pilot confirmed plasma half-life under 30 min. No validated pharmaceutical-grade formulation exists. No PMID 42198317 Mateescu DM, et al. Pharmaceutics. 2026.
Safety signals
- No adverse events reported in the 12-patient intravesical pilot study for interstitial cystitis. PMID 39325560
- No adverse reactions reported in the majority of preclinical animal studies reviewed; lethal dose not achieved in animal safety studies. PMID 36551977
- Only a few side effects have been reported following BPC-157 administration across preclinical models; described as having a 'desirable safety profile'. PMID 40005999
- No adverse effects across several organ systems found in preclinical safety studies; no clinical safety data were found in the systematic review. PMID 40756949
- Adverse effects considered possible due to unregulated manufacturing, contamination, or unknown clinical safety — not from the compound itself in controlled studies. PMID 40756949
- No reported toxicity (LD1 not achieved) noted in prior ulcerative colitis and multiple sclerosis trials referenced in wound healing review. PMID 34267654
- The precise healing mechanisms are not fully understood, and there is still a need to understand them for clinical realisation. PMID 30915550
Contraindications
- No formal contraindications are established in the reviewed literature. BPC-157 is not approved for any indication and has no validated clinical dosing or safety profile. Use is contraindicated outside of research/supervised clinical settings given the absence of Phase II trial data. PMID 42198317
- Prohibited at all times under WADA S0 (non-approved substances), per the 2026 World Anti-Doping Code Prohibited List. Verified against the current WADA list as of October 2026. WADA 2026 Prohibited List
Protocol
250 mcg subcutaneous injection, once daily. Cycle: 4-6 weeks.
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| Intravesical injection (around area of bladder inflammation) | 10 mg total | Single procedure | human | Research PMID 39325560 |
| Intraperitoneal, drinking water, or topical | µg–ng regimens (specific values not stated in abstract) | Not specified in abstract | animal | Research PMID 36551977 |
| Multiple routes (oral, parenteral, topical) described as equipotent | Same dose range across equipotent routes (specific values not stated in abstract) | Not specified in abstract | animal | Research PMID 34267654 |
| subcutaneous injection | 250 mcg | once daily · 4-6 weeks | biohackers and athletes for localized injury recovery | [Community] |
| subcutaneous injection | 500 mcg | once daily · 4-6 weeks | biohackers and athletes for localized injury recovery | [Community] |
| subcutaneous injection | 250 mcg | twice daily · 4-6 weeks | athletes and biohackers with acute or severe injuries | [Community] |
| intramuscular injection | 500 mcg | once daily · 4-6 weeks | athletes targeting deep muscle or joint injuries | [Community] |
| oral (capsule or dissolved in water) | 250 mcg | once daily · 4-8 weeks | biohackers and individuals with GI tract issues (IBS, leaky gut, gastric ulcers) | [Community] |
| oral (capsule or dissolved in water) | 500 mcg | once daily · 4-8 weeks | biohackers and individuals with GI tract conditions | [Community] |
| sublingual (dissolved under tongue) | 250 mcg | once daily · 4-6 weeks | biohackers seeking needle-free systemic or GI effects | [Community] |
| subcutaneous injection | 500 mcg | once daily · 12 weeks | biohackers using BPC-157 for longevity and systemic anti-inflammatory effects | [Community] |
| subcutaneous injection | 500 mcg | 5 days on, 2 days off · 4-8 weeks | biohackers and athletes following structured peptide cycling protocols | [Community] |
| subcutaneous injection | 1000 mcg | once daily · 4-6 weeks | experienced biohackers or those with severe/chronic injuries | [Community] |
| subcutaneous injection | 500 mcg | once daily · 4-6 weeks | post-cycle (anabolic steroid) recovery users seeking tissue and joint repair | [Community] |
| subcutaneous injection | 250 mcg | once daily · 4-6 weeks | biohackers and athletes stacking BPC-157 with TB-500 for synergistic healing | [Community] |
The BPC-157 + TB-500 stack: what the one direct study found
BPC-157 + TB-500 is widely promoted online as THE healing stack. The only published study directly testing the combination — a rat Achilles tendon model (PMID: 42542926, 2026) — found no additive benefit over BPC-157 alone. No human trials on the combination exist.
Read our full blend review →Stacks and blends containing this peptide
All studies (10)
- PMID 39325560 Human observational
Interstitial cystitis (bladder pain syndrome) - PMID 42198317 Mixed
Biopharmaceutical characterization and pharmacokinetics - PMID 30915550 Animal studies only
Musculoskeletal soft tissue healing (tendon, ligament, skeletal muscle, bone) - PMID 34267654 Animal studies only
Wound healing (skin, gastrointestinal, and other tissues) - PMID 36551977 Animal studies only
Musculoskeletal soft tissue healing (tendon, ligament, skeletal muscle, bone) - PMID 37513963 Animal studies only
Ocular conditions including glaucoma, retinal ischemia, and corneal injury - PMID 39204186 Animal studies only
Gastrointestinal anastomosis healing and fistula therapy - PMID 40005999
Only a few side effects have been reported following BPC-157 administration across preclinical models; described as having a 'desirable safety profile'. - PMID 40756949 Animal studies only
Musculoskeletal soft tissue healing (tendon, ligament, skeletal muscle, bone) - PMID 40789979 Animal studies only
Musculoskeletal soft tissue healing (tendon, ligament, skeletal muscle, bone)
Frequently asked
What is BPC-157 and where does it come from?
BPC-157, or Body Protection Compound 157, is a synthetic pentadecapeptide (15-amino-acid peptide) originally derived from a fragment of a human gastric protein. It is reported to have cytoprotective and regenerative properties across multiple organ systems. It is stable in gastric juice and has been studied via oral, parenteral, and topical routes in preclinical models (PMID 42198317, PMID 40005999).
What has BPC-157 been studied for?
Published preclinical and limited clinical research has examined BPC-157 for: musculoskeletal soft tissue healing (tendons, ligaments, muscle, bone) (PMID 30915550, PMID 40756949); wound healing including burns and diabetic ulcers; gastrointestinal anastomosis healing and fistula therapy in animal models; ocular conditions including glaucoma in rat models; and interstitial cystitis in a small human pilot study. The overwhelming majority of evidence is from animal studies, with very limited human data.
What dose of BPC-157 should I take?
I'm not a medical professional and can't recommend a protocol for you specifically. What research has shown: The only published human dosing used 10 mg total via intravesical injection in 12 women with interstitial cystitis during a single cystoscopy procedure. Animal studies have used µg–ng dose regimens via intraperitoneal, oral, or topical routes. No validated human dosing regimen exists as of the reviewed literature.
Is BPC-157 safe? Are there any side effects?
Based on the reviewed literature: No adverse events were reported in the 12-patient human pilot study, and preclinical animal studies have not achieved a lethal dose and report few side effects (PMID 36551977, PMID 40005999). However, human clinical safety data are extremely limited — fewer than 30 subjects across three uncontrolled pilot studies. Adverse effects are considered possible due to unregulated manufacturing, contamination, or unknown clinical safety. No pharmaceutical-grade formulation exists, and long-term human safety is unknown. Consult a licensed healthcare provider before use.
Is BPC-157 FDA-approved?
No. BPC-157 is not approved by the US Food and Drug Administration for any therapeutic indication (PMID 39325560, PMID 40005999). No completed Phase II clinical trial has been conducted as of the reviewed literature. The reviewed abstracts note it has been manufactured by compounding pharmacies in at least one human study.
Is BPC-157 banned by WADA or in professional sports?
Prohibited at all times under WADA S0 (non-approved substances), per the 2026 World Anti-Doping Code Prohibited List. Verified against the current WADA list as of October 2026.
Can BPC-157 help my tendon or ligament injury?
I can't suggest treatments for medical conditions. Please speak with a licensed healthcare provider. What the research shows: Preclinical animal studies have consistently demonstrated positive healing effects for tendon, ligament, and muscle injuries (PMID 30915550, PMID 40756949). One small retrospective human study (n=12) reported that 7 of 12 patients with chronic knee pain had relief for more than 6 months after intraarticular injection. However, no large-scale controlled human trials have been conducted, and efficacy in humans remains unconfirmed.
What is the half-life of BPC-157 and how long does it stay in the body?
Based on the reviewed literature, BPC-157 has a plasma half-life of less than 30 minutes, confirmed in preclinical studies across two species and in a preliminary two-subject human pilot study (PMID 42198317, PMID 40756949). Despite this short half-life, biological effects lasting hours to days have been observed in preclinical studies — a disconnect that has significant implications for dosing strategy. It is metabolized in the liver and cleared by the kidneys. Human pharmacokinetic data beyond this preliminary pilot are critically undercharacterized.
Can I stack BPC-157 with other peptides or compounds?
I can't recommend combining compounds — that's a prescribing decision. Here's what has been studied individually: BPC-157 has been studied as a standalone agent in animal models and very limited human pilots (PMID 30915550, PMID 39325560, PMID 40756949). No reviewed abstracts address combination use with other peptides or compounds.
Where can I buy BPC-157?
I don't recommend vendors or sources. Please consult a licensed provider. Note that BPC-157 is not FDA-approved and lacks a validated pharmaceutical-grade formulation; the reviewed literature flags risks from unregulated manufacturing and contamination.